BPC-157 5 mg + TB-500 5 mg. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.
The studies behind this compound did not test timing or food state as variables, so we are not going to invent a rule. Pick a time you can keep to consistently.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Weeks 1–2 | 500 mcg | daily | 0.1 mL | 10 u | 14 | 7 mg |
| Weeks 3–4 | 1000 mcg | daily | 0.2 mL | 20 u | 14 | 14 mg |
| Week 5 onward per 4 weeks from here on |
1500 mcg | daily | 0.3 mL | 30 u | 28 | 42 mg |
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial |
|---|---|---|---|---|---|
| Low reported | 500 mcg | 1× daily · 250 mcg of each compound | 0.1 mL | 10 u | 20 doses |
| Standard | 1000 mcg | 1× daily · 500 mcg of each compound | 0.2 mL | 20 u | 10 doses |
| Upper reported | 1500 mcg | 1× daily · 750 mcg of each compound | 0.3 mL | 30 u | 6 doses |
The most common repair blend, equal parts BPC-157 and TB-500. Two sizes: the 10 mg vial holds 5 mg of each, the 20 mg vial holds 10 mg of each. The split is 50/50 either way, so every dose delivers half of it to each component regardless of which vial you have — a 1000 mcg dose is 500 mcg of each. The vial size changes how many doses you get, not the ratio. Switch the vial strength above to match what you are holding.
Buy Wolverine BlendPaid affiliate links.
Adding 2 mL of bacteriostatic water to a 10 mg vial gives 5 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.
Published and reported figures for Wolverine Blend run from 500 mcg to 1500 mcg, typically 1× daily (250 mcg each). This site lists each figure with the source it came from rather than giving a single recommended number.
At 5 mg/mL, a 500 mcg dose is 10 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 20 doses.
Wolverine Blend is graded preclinical. Laboratory and animal data only. No human dosing trials have been published. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.
This is the most common repair pairing, and it is an even split. Both compounds are studied for tissue repair, but the preclinical work points at different parts of the process — BPC-157 more toward tendon, ligament and gut, TB-500 more toward cell migration and remodelling.
The argument for combining them is that those are complementary rather than overlapping mechanisms. It is worth being clear that this is a reasoned argument, not a demonstrated one: there is no published human trial of either compound alone, let alone together.
Compounds in the same class, or browse the full catalogue.
An equal-parts repair and anti-inflammatory pairing — 10 mg of each in a 20 mg vial, so every dose splits evenly down the middle a…
A GHRH analogue paired with a selective ghrelin receptor agonist — the pairing rationale is that the two receptors act synergistic…
Every compound compared in one table: dose range, how often, half-life and evidence tier.
Need this on one page to print, screenshot or send?
Make a dose card →